Prof Peters
Brahmer JR et al. Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227. ASCO 2024;Abstract LBA9025.
Carlisle JW et al. Bispecific antibodies in non-small cell lung cancer: From targeted innovation to real-world integration. Am Soc Clin Oncol Educ Book 2025;45(3). Abstract
Garon EB et al. A brief report of durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: Outcomes by tumor PD-L1 expression in the phase 3 POSEIDON study. Clin Lung Cancer 2024;25(3):266-73. Abstract
Kilickap S et al. Cemiplimab monotherapy for first line advanced NSCLC patients with PD-L1 expression ≥50%: 5-y outcomes of EMPOWER-Lung. WCLC 2024;Abstract OA11.06.
Peters S et al. Treatment-free survival over 6 years of follow-up in patients with metastatic non-small cell lung cancer treated with first-line nivolumab plus ipilimumab versus chemotherapy in CheckMate 227 part 1. J Thorac Oncol 2025;[Online ahead of print]. Abstract
Zhou C et al. Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC). ESMO 2024;Abstract 1318P.
Prof Garassino
Camidge DR et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing advanced non-small cell lung cancer. ASCO 2022;Abstract 9016.
Girard N et al. Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial. ELCC 2025;Abstract 10MO.
Janne PA et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. ASCO 2024;Abstract 8543.
Le X et al. METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence. ESMO 2024;Abstract 1303P.
Lu S et al. A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01). ASCO 2024;Abstract TPS8656.
Planchard D et al. Trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing nonsquamous non-small cell lung cancer: DESTINY-Lung03 part 1. WCLC 2024;Abstract OA16.05.
Dr Sands
Ahn SG et al. A prognostic value of BCT gene score in ER+HER2- breast cancer patients with 21-gene recurrence score. ESMO Asia 2024;Abstract 10.
Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01. WCLC 2024;Abstract PL02.11.
Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501.
Paz-Ares LG et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III EVOKE-01 study. J Clin Oncol 2024;42(24):2860-72. Abstract
Sands J et al. Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: Final overall survival from TROPION-Lung01. WCLC 2024;Abstract OA08.03.
Zhao S et al. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: Phase 1/2 and phase 2 trials. Nat Med 2025;[Online ahead of print]. Abstract
Dr Heymach
Cascone T et al. Neocoast-2: Efficacy and safety of neoadjuvant durvalumab (D) + novel anticancer agents + CT and adjuvant D ± novel agents in resectable NSCLC. IASLC 2024;Abstract PL02.07.
Cascone T et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med 2024;390(19):1756-69. Abstract
Forde PM et al. Perioperative vs neoadjuvant nivolumab for resectable NSCLC: Patient-level data analysis of CheckMate 77T vs CheckMate 816. WCLC 2024;Abstract PL02.08.